Wacker Biotech GmbH
General information
Wacker Biotech GmbH
Hans-Knöll-Str. 3
07745 Jena, Thuringia
Germany
Contact person: Laura Müller, Business Development Manager
Company main phone: +49 (3641) 53480
Website: https://www.wacker.com/biologics
Hans-Knöll-Str. 3
07745 Jena, Thuringia
Germany
Contact person: Laura Müller, Business Development Manager
Company main phone: +49 (3641) 53480
Website: https://www.wacker.com/biologics
| Year founded: | 1999 |
| Source of foundation: | Spin-off from university |
| Name of foundation source: | Hans Knöll Institute |
| No. of employees: | At this location: 160 |
Corporate description / mission:
Wacker Biotech GmbH is a contract manufacturer of therapeutic proteins (biologics), vaccines and live microbial products.
Wacker Biotech’s services cover cell banking, process & analytical development and the GMP manufacturing of biologics for clinical & commercial supply.
Wacker Biotech GmbH is a contract manufacturer of therapeutic proteins (biologics), vaccines and live microbial products.
Wacker Biotech’s services cover cell banking, process & analytical development and the GMP manufacturing of biologics for clinical & commercial supply.
State of ownership: Subsidiary
Headquarters: No
Headquarters: No
Remarks on ownership / listings
Subsidiary of Wacker Chemie AG.
In 2005, WACKER acquired the Jena-based biotech company ProThera GmbH and changed name to Wacker Biotech GmbH.
In 2013, WACKER Biotech acquired and integrated former Scil Proteins Production in Halle, Germany. The acquisition included a 1500l GMP biomanufacturing facility as well as production-related intellectual property.
Subsidiary of Wacker Chemie AG.
In 2005, WACKER acquired the Jena-based biotech company ProThera GmbH and changed name to Wacker Biotech GmbH.
In 2013, WACKER Biotech acquired and integrated former Scil Proteins Production in Halle, Germany. The acquisition included a 1500l GMP biomanufacturing facility as well as production-related intellectual property.
Categorization
| Sector: |
|
| Subsector: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Description of products:
Recombinant proteins (contract manufacturing)
Recombinant proteins (contract manufacturing)
Technology used:
ESETEC® secretion technology
FOLDTEC® technology
LIBATEC® platform
ESETEC® secretion technology
FOLDTEC® technology
LIBATEC® platform
Collaborations & Clients
Partnering strategy / collaborations:
Wacker Biotech and XL-protein have signed a long-term cooperation agreement to produce PASylated biopharmaceuticals. Through this collaboration, WACKER and its customers gain access to XL-protein's PASylation® platform. The PASylation® technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly. Recently, record yields of 4.3 g/L were obtained for PASylated Fabs using Wacker's ESETEC E. coli secretion technology.
Wacker Biotech and XL-protein have signed a long-term cooperation agreement to produce PASylated biopharmaceuticals. Through this collaboration, WACKER and its customers gain access to XL-protein's PASylation® platform. The PASylation® technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly. Recently, record yields of 4.3 g/L were obtained for PASylated Fabs using Wacker's ESETEC E. coli secretion technology.
© 2023 Biotechgate by Venture Valuation